摘要
抗凋亡蛋白Bcl-2抑制剂维奈克拉(Ven)能够显著改善不适合强化化疗的老年以及复发/难治的急性髓系白血病(AML)患者的缓解率和远期生存。临床治疗中伴随出现TP53/FLT3突变、异常脂肪酸及氨基酸的能量代谢、Mcl-1蛋白的高表达以及铁死亡程序的激活等多种机制,参与了Ven耐药发生和白血病进展。深入探索导致Ven治疗髓系白血病耐药的机制,有助于克制Ven耐药产生和持续改善白血病患者的远期生存。
The anti-apoptotic protein Bcl-2 inhibitor venetoclax(Ven)can significantly improve the remission rate and long-term survival of elderly and relapsed/refractory acute myeloid leukemia(AML)patients who are not sensitive to intensive chemotherapy.TP53/FLT3 mutation,abnormal energy metabolism of fatty acids and amino acids,high expression of Mcl-1 protein and activation of ferroptosis program occur during clinical treatment are all involved in the development of Ven resistance and leukemia progression.Further exploration of the mechanisms leading to Ven resistance in myeloid leukemia may help to inhibit the development of Ven resistance and continuously improve the long-term survival of leukemia patients.
作者
向彩霞
黄彬涛
郝建
XIANG Caixia;HUANG Bintao;HAO Jian(Department of Hematology,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010059,China;Department of Nephrology,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010059,China)
出处
《基础医学与临床》
2023年第5期833-836,共4页
Basic and Clinical Medicine
基金
内蒙古自然科学基金(2019MS08028)
内蒙古医科大学校级面上项目(YKD2022MS014)。
